Conavi Medical’s Novasight Hybrid™ System Named “Product Innovation of the Year” at 2025 Minnesota Manufacturing Awards
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) announced that its Novasight Hybrid™ System has been awarded "Product Innovation of the Year" at the 2025 Minnesota Manufacturing Awards. The Novasight system is pioneering as the first commercial device to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies for simultaneous, co-registered imaging of coronary arteries. This innovative technology provides interventional cardiologists with comprehensive insights during complex coronary procedures.
The award, presented by the Minneapolis/St. Paul Business Journal, recognizes Conavi's collaboration with Minnesota-based Minnetronix Medical. The company and its technology will be featured in a special publication on July 18, 2025.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) ha annunciato che il suo Novasight Hybrid™ System è stato premiato come "Innovazione di Prodotto dell'Anno" ai Minnesota Manufacturing Awards 2025. Il sistema Novasight è pionieristico in quanto primo dispositivo commerciale a combinare tecnologie di ultrasuoni intravascolari (IVUS) e tomografia a coerenza ottica (OCT) per immagini simultanee e co-registrate delle arterie coronarie. Questa tecnologia innovativa offre agli cardiologi interventisti una visione completa durante procedure coronariche complesse.
Il premio, consegnato dal Minneapolis/St. Paul Business Journal, riconosce la collaborazione di Conavi con Minnetronix Medical, con sede in Minnesota. L'azienda e la sua tecnologia saranno protagoniste di una pubblicazione speciale il 18 luglio 2025.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) anunció que su Novasight Hybrid™ System ha sido galardonado con el premio "Innovación de Producto del Año" en los Premios de Manufactura de Minnesota 2025. El sistema Novasight es pionero al ser el primer dispositivo comercial que combina tecnologías de ultrasonido intravascular (IVUS) y tomografía de coherencia óptica (OCT) para obtener imágenes simultáneas y co-registradas de las arterias coronarias. Esta tecnología innovadora proporciona a los cardiólogos intervencionistas una visión integral durante procedimientos coronarios complejos.
El premio, otorgado por el Minneapolis/St. Paul Business Journal, reconoce la colaboración de Conavi con Minnetronix Medical, con sede en Minnesota. La compañía y su tecnología serán destacadas en una publicación especial el 18 de julio de 2025.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF)는 자사의 Novasight Hybrid™ System이 2025 미네소타 제조상에서 "올해의 제품 혁신상"을 수상했다고 발표했습니다. Novasight 시스템은 관상동맥의 동시 및 정합 이미징을 위해 혈관 내 초음파(IVUS)와 광학 단층 촬영(OCT) 기술을 결합한 최초의 상업용 장치로 선도적인 역할을 하고 있습니다. 이 혁신적인 기술은 복잡한 관상동맥 시술 중 중재 심장 전문의에게 종합적인 통찰력을 제공합니다.
이 상은 Minneapolis/St. Paul Business Journal에서 수여했으며, Conavi와 미네소타에 본사를 둔 Minnetronix Medical의 협력을 인정하는 것입니다. 회사와 기술은 2025년 7월 18일 특별 간행물에 소개될 예정입니다.
Conavi Medical (TSXV : CNVI ; OTCQB : CNVIF) a annoncé que son Novasight Hybrid™ System a reçu le prix de « Produit Innovant de l’Année » aux Minnesota Manufacturing Awards 2025. Le système Novasight est une innovation majeure, étant le premier dispositif commercial à combiner l’échographie intravasculaire (IVUS) et la tomographie par cohérence optique (OCT) pour une imagerie simultanée et co-enregistrée des artères coronaires. Cette technologie innovante offre aux cardiologues interventionnels une vision complète lors de procédures coronariennes complexes.
Ce prix, remis par le Minneapolis/St. Paul Business Journal, souligne la collaboration de Conavi avec Minnetronix Medical, basée dans le Minnesota. L’entreprise et sa technologie seront mises en avant dans une publication spéciale le 18 juillet 2025.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) gab bekannt, dass sein Novasight Hybrid™ System mit dem Preis "Produktinnovation des Jahres" bei den Minnesota Manufacturing Awards 2025 ausgezeichnet wurde. Das Novasight-System ist bahnbrechend als erstes kommerzielles Gerät, das intravaskulären Ultraschall (IVUS) und optische Kohärenztomographie (OCT) Technologien zur gleichzeitigen, ko-registrierten Bildgebung der Koronararterien kombiniert. Diese innovative Technologie bietet interventionellen Kardiologen umfassende Einblicke während komplexer Koronarverfahren.
Der Preis, verliehen vom Minneapolis/St. Paul Business Journal, würdigt die Zusammenarbeit von Conavi mit dem in Minnesota ansässigen Unternehmen Minnetronix Medical. Das Unternehmen und seine Technologie werden in einer Sonderveröffentlichung am 18. Juli 2025 vorgestellt.
- First commercial device to integrate IVUS and OCT imaging technologies
- Recognition from prestigious Minnesota Manufacturing Awards enhances company credibility
- Strategic partnership with Minnetronix Medical demonstrates strong development capabilities
- Product still in development phase, pending commercial launch
- Market adoption and commercial success yet to be proven
Award recognizes Novasight Hybrid™ System’s significant advance in intracoronary imaging technology
TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Novasight Hybrid™ System (“Novasight”) has been named "Product Innovation of the Year" at the 2025 Minnesota Manufacturing Awards.
"This award is another powerful validation of our vision for Novasight," said Thomas Looby, Conavi Medical’s CEO. "We’re proud to share it with Minnetronix Medical, our Minnesota-based development partner – their expertise and commitment made this award possible. As we work toward commercial launch of our next-generation Novasight, we are honoured to win this prestigious award in Minnesota, a world-leading location for medical device technology."
Novasight is the first commercial device to integrate intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous, co-registered imaging of coronary arteries. This unique technology provides interventional cardiologists with unparalleled, comprehensive insights during complex coronary procedures, enhancing their ability to make critical decisions required to deliver optimal patient outcomes.
The Minnesota Manufacturing Awards, presented annually by the Minneapolis/St. Paul Business Journal, celebrate the innovation, leadership, and growth of Minnesota's vibrant manufacturing industry. Conavi Medical and Novasight will be spotlighted in the Minneapolis/St. Paul Business Journal's special "Minnesota Manufacturing Awards" publication on July 18, 2025. For more information on the award, and to view a complete list of honorees, see the Business Journal's announcement: https://www.bizjournals.com/twincities/business-of-manufacturing
About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit conavi.com.
Notice on forward-looking statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the Offering. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking information or statements". Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate" "anticipate" or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the "Risk Factors" section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at www.sedarplus.ca). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
CONTACT: Stefano Picone Chief Financial Officer (416) 483-0100
FAQ
What is the Novasight Hybrid System by Conavi Medical (CNVIF)?
What award did Conavi Medical (CNVIF) win in May 2025?
Who is Conavi Medical's development partner for the Novasight Hybrid System?
What are the benefits of Conavi Medical's Novasight Hybrid System?
